However, these haemolytic assays are all cumbersome and difficult

However, these haemolytic assays are all cumbersome and difficult to standardize. Several enzyme-linked immunosorbent assays (ELISA) for the assessment of the functional activity of the complement activation pathways have been described,

but the use of these assays in routine clinical practice is limited. However, a well-described functional ELISA-based procedure for all the three pathways has been described recently and is available as a commercial kit (WIESLAB® Complement System Screen Rucaparib COMPL 300; Euro-Diagnostica, Malmö, Sweden). Although the Wielisa assay performs satisfactorily, it is subject to some major limitations related to the measurement of the MBL pathway. The main problem associated with assessment of MBL complement capacity on a mannan-coated

find more surface is interference from the CP and the AP. In the Wielisa kit the CP activity is eliminated using an antibody that inhibits C1q binding, but a possible interference from the AP is not removed and the sample measurements must be performed with predetermined high serum dilution (1:101) to avoid this. This approach holds the potential pitfalls of inducing false negative results if the assay is performed at too high a serum dilution, or false positive results if the dilution is to low. Consequently, in light of the clinical relevance of MBL deficiencies, it is important for an MBL assay to measure MBL activity exclusively without any interference from the CP and the AP, and thus to also be applicable at low serum dilutions. In the present study, we describe optimized ELISA-based assays for the measurements of the functional why capacities of the three complement pathways. The assays are validated by analysis of serum samples from 150 healthy blood donors and from 30 patients with assorted deficiencies within complement components. For assessment of the MBL pathway we utilize a polyanion compound, sodium polyanethole sulphonate (SPS), which has been described

recently to inhibit both the AP and the CP leaving the MBL pathway unaffected. Thus, it allows for a specific measurement of the functional capacity of the MBL pathway without the need for a high serum dilution [18]. Additionally, we have developed modified and optimized assays specific for the AP and the CP pathways to measure the functional capacity of these pathways. Serum samples were obtained from 150 healthy blood donors, 68 females with a mean age of 43·4 years (range 21–67 years) and 82 males with a mean age of 45·0 years (range 21–66 years). Blood was allowed to clot at room temperature for 2 h followed by centrifugation at 970 g at 4°C for 15 min. After centrifugation, serum was removed from the clot, aliquoted into 150-µl portions and stored at −80°C until further analysis. Sera from 30 patients with described complement deficiencies were collected and tested in the present assays.

Related posts:

  1. All assays were performed under conditions in which the product w
  2. Alamar Blue and IN Cell one thousand screening assays Cells wer
  3. All antibody positive samples also contained neutralizing antibod
  4. 3-D assays that respond with organ-specific biomarkers are useful to Vargatef and Afatinib
  5. It is difficult to correlate in vitro toxin concentration with in
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>